Skip to main content
. 2022 Nov 1;8(11):2242–2252. doi: 10.1021/acsinfecdis.2c00459

Figure 2.

Figure 2

Reported BAM complex inhibitors: MRL-494 (1),15 darobactin (2),16 VUF15259 (3),184, 5,19 and 6.20 MRL-494 (1) and VUF15259 (3) are both reported as racemic mixtures at the position denoted with *.